Dr. Remo Panaccione, an internationally recognized expert in clinical trials discusses the recent data on vedolizumab and anti-IL23 therapies and how those changes impact clinical decision making in IBD
Comments
0
Be the first to comment
Sign up now and become a member of the IBD Essentials community!
Comments
0Be the first to comment
Sign up now and become a member of the IBD Essentials community!